JP2021517135A - 化学療法抵抗性がんの組合せ処置 - Google Patents

化学療法抵抗性がんの組合せ処置 Download PDF

Info

Publication number
JP2021517135A
JP2021517135A JP2020547097A JP2020547097A JP2021517135A JP 2021517135 A JP2021517135 A JP 2021517135A JP 2020547097 A JP2020547097 A JP 2020547097A JP 2020547097 A JP2020547097 A JP 2020547097A JP 2021517135 A JP2021517135 A JP 2021517135A
Authority
JP
Japan
Prior art keywords
ror
antibody
ror1
chemotherapeutic agent
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020547097A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517135A5 (https=
JPWO2019173843A5 (https=
Inventor
キップス，トーマス
ジャン，スウピン
ギア，エマヌエラ・エム
Original Assignee
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア filed Critical ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア
Publication of JP2021517135A publication Critical patent/JP2021517135A/ja
Publication of JP2021517135A5 publication Critical patent/JP2021517135A5/ja
Publication of JPWO2019173843A5 publication Critical patent/JPWO2019173843A5/ja
Priority to JP2025003271A priority Critical patent/JP2025063134A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2020547097A 2018-03-09 2019-03-11 化学療法抵抗性がんの組合せ処置 Pending JP2021517135A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025003271A JP2025063134A (ja) 2018-03-09 2025-01-09 化学療法抵抗性がんの組合せ処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862641035P 2018-03-09 2018-03-09
US62/641,035 2018-03-09
PCT/US2019/021694 WO2019173843A1 (en) 2018-03-09 2019-03-11 Combination treatment of chemoresistant cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025003271A Division JP2025063134A (ja) 2018-03-09 2025-01-09 化学療法抵抗性がんの組合せ処置

Publications (3)

Publication Number Publication Date
JP2021517135A true JP2021517135A (ja) 2021-07-15
JP2021517135A5 JP2021517135A5 (https=) 2022-03-18
JPWO2019173843A5 JPWO2019173843A5 (https=) 2022-03-18

Family

ID=67846369

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020547097A Pending JP2021517135A (ja) 2018-03-09 2019-03-11 化学療法抵抗性がんの組合せ処置
JP2025003271A Pending JP2025063134A (ja) 2018-03-09 2025-01-09 化学療法抵抗性がんの組合せ処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025003271A Pending JP2025063134A (ja) 2018-03-09 2025-01-09 化学療法抵抗性がんの組合せ処置

Country Status (6)

Country Link
US (1) US11883492B2 (https=)
EP (1) EP3762428A4 (https=)
JP (2) JP2021517135A (https=)
CN (1) CN112262157A (https=)
AU (1) AU2019231321B2 (https=)
WO (1) WO2019173843A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250008730A (ko) 2022-03-09 2025-01-15 산유 바이오파마슈티컬스 씨오., 엘티디. Ror1-표적화 결합 분자 및 이의 용도
CN120865418B (zh) * 2025-09-28 2025-12-30 成都微芯新域生物技术有限公司 抗ror1抗体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509889A (ja) * 2008-11-22 2012-04-26 ジェネンテック， インコーポレイテッド 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用
JP2013529203A (ja) * 2010-05-14 2013-07-18 ジェネンテック， インコーポレイテッド 治療方法
JP2016501213A (ja) * 2012-12-04 2016-01-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がんの処置におけるエリブリンの使用
WO2018005519A2 (en) * 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3252076T3 (da) * 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
PL3489261T3 (pl) * 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
EP3842072A1 (en) * 2015-05-18 2021-06-30 Eureka Therapeutics, Inc. Anti-ror1 antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509889A (ja) * 2008-11-22 2012-04-26 ジェネンテック， インコーポレイテッド 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用
JP2013529203A (ja) * 2010-05-14 2013-07-18 ジェネンテック， インコーポレイテッド 治療方法
JP2016501213A (ja) * 2012-12-04 2016-01-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がんの処置におけるエリブリンの使用
WO2018005519A2 (en) * 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANCER RES., vol. 76 (14_Supplement), JPN6023051640, 2016, pages 1193, ISSN: 0005411945 *
CANCER RES., vol. 78 (4_Supplement), JPN6023010635, February 2018 (2018-02-01), pages 1 - 09, ISSN: 0005411944 *
CLINICALTRIALS.GOV ARCHIVE NCT02776917 ON 2017_05_10, RETRIEVED FROM THE INTERNET, JPN6023051639, 10 May 2017 (2017-05-10), ISSN: 0005411946 *
PLOS ONE, vol. 7(3), JPN6023051638, 2012, pages 31127 - 1, ISSN: 0005221439 *

Also Published As

Publication number Publication date
CA3093568A1 (en) 2019-09-12
US11883492B2 (en) 2024-01-30
US20210085786A1 (en) 2021-03-25
AU2019231321A1 (en) 2020-10-15
EP3762428A1 (en) 2021-01-13
AU2019231321B2 (en) 2026-01-29
WO2019173843A1 (en) 2019-09-12
EP3762428A4 (en) 2021-12-01
JP2025063134A (ja) 2025-04-15
CN112262157A (zh) 2021-01-22

Similar Documents

Publication Publication Date Title
JP2023179437A (ja) キメラ抗原受容体組成物
JP2019108330A (ja) ｅＩＦ２α経路の調節因子
JP2020533960A (ja) 抗ｉｌ１ｒａｐ抗体
JP7091244B2 (ja) デオキシシチジンキナーゼ結合化合物
JP2025063134A (ja) 化学療法抵抗性がんの組合せ処置
IL293026A (en) Anti-ror-2 antibodies and methods of using them
US20240400686A1 (en) Anti-cd3 antibodies and uses thereof
US20210023238A1 (en) Triptolide antibody conjugates
US20250353924A1 (en) Anti-cd84 antibodies and uses thereof
JP2023550049A (ja) Ｉｒｅ１アルファ阻害剤及びその使用
US20260008864A1 (en) Bispecific anti-cd38-cd3 binders
CN116916900A (zh) 用于治疗膀胱癌的低氧诱导因子-2（α）抑制剂
CA3093568C (en) Combination treatment of chemoresistant cancers
JP2024505093A (ja) 神経内分泌がんの治療
US20240132887A1 (en) Protein arginine methyltransferase 9 inhibitors and methods of use
US20250361315A1 (en) Humanized anti-cd84 recombinant protein compositions
HK40046118A (en) Combination treatment of chemoresistant cancers
KR20240046558A (ko) 항-수용체 관련 티로신 키나제 (ryk) 항체 및 이의 용도
KR20250129736A (ko) 항-ror-2 항체 및 사용 방법
US20230340089A1 (en) Smc1a antibodies and uses thereof
HK40115498A (zh) 抗-cd84抗体以及其用途
JP2020518251A (ja) 抗体可変ドメイン及び抗体構築物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240619

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240910